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LOH at 3p correlates with a poor survival in oral squamous cell carcinoma
M Partridge, G Emilion and JD Langdon
Epithelial Cell Biology Unit/Department of Oral and Maxillofacial Surgery, King's College School ofMedicine and Dentistry,
Denmark Hill, London SE5 8RX, UK.
Summary We analysed chromosome 3p for loss of heterozygosity (LOH) in 48 primary oral squamous cell
carcinomas (SCCs) using 15 markers and constructed a deletion map for this chromosome arm. LOH at one or
more loci was found in 34/48 (71%) of tumours. The data support the existence of at least three distinct regions
of deletion at 3p24-26, 3p2l.3-22.1 and 3pl2.1-14.2. A significant correlation was observed between the
number of regions showing allele loss at 3p and tumour stage, consistent with the progressive accumulation of
genetic errors during the development of oral SCC. There were also significant associations between LOH at 3p
and disease-free and overall survival of patients with early stage disease. This study is the first to demonstrate
the prognostic significance of LOH at 3p for oral cancer and may help to identify patients who should receive
more aggressive treatment.
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When cancer is first diagnosed, treatment for an individual is
based on an estimation of the expected behaviour of the
tumour and the patients prognosis, with aggressive disease
requiring more aggressive treatment. At present, prognostic
information for oral cancer is obtained after taking into
account the clinical stage of the tumour and after
microscopical examination of tissue obtained following
biopsy. However, tumours that appear similar morphologi-
cally and histologically will show varying responses when
treated in identical ways.
The results of treatment for oral cancer have remained at a
disappointingly stable level for many years. Current
treatment protocols may not offer the best chance of long-
term survival (Henk and Langdon, 1994). Many patients
develop local or nodal recurrence within 2 years (Hirata et
al., 1975) and may develop a second primary tumour in the
upper aerodigestive tract (Carr and Langdon, 1989).
Although surgical techniques have developed in recent years
and local control of this disease has improved, more patients
are developing metastatic disease within 5 years (Luna, 1983)
and the chances of long palliation with radiotherapy or
chemotherapy are slight. In order to improve management of
oral cancer patients we need to develop a better under-
standing of the biological diversity that exists within lesions
that appear similar morphologically, to identify their
potential for progression accurately and to use this
information to modify existing treatment regimens to
improve clinical course and outcome.
Chromosomal deletions at 3p have been reported for
tumours of the lung, kidney, breast, uterine cervix,
endometrium, ovary, testes, head and neck and oral cavity
(reviewed by Jones and Nakamura, 1992) and three regions
have been identified that may harbour tumour-suppressor
genes. We have prepared a deletion map for chromosome 3p
for oral squamous cell carcinoma (SCC) and related the
findings to clinicopathological features of these tumours as
knowledge gained from this type of study may identify new
prognostic markers. The results show that loss of hetero-
zygosity (LOH) at 3p is a marker of poor prognosis for oral
cancer as determined by reduced disease-free and overall
survival of patients with early stage disease.
Methods
A total of 48 primary oral SCC were snap frozen in liquid
nitrogen immediately after surgical resection and stored at
-70'C. Venous blood was stored in sodium chloride-EDTA
tubes and kept at -20°C until required. In some cases
normal mucosa obtained from the opposite side of the mouth
was also available as a control. Ethical Committee Approval
for this project was granted at King's College Hospital.
Patients were staged clinically according to 1978 UICC TNM
criteria and restaged following histopathological examination
of the resection specimen if the initial nodal status was
incorrect. The minimum period of follow-up in the study was
24 months.
Frozen (10 gum) sections were mounted onto microscope
slides and stained with toluidine blue before microdissection
to remove as much normal tissue as possible and ensure a
maximum percentage of tumour in each specimen. All
tumour specimens used in this study contained more than
50% tumour tissue. Once the dissection was complete
samples were digested in 100 pl of lysis buffer (Wright and
Manos, 1990). Genomic DNA was extracted from venous
blood by lysis with Triton-X100. To examine LOH at THRB,
D3S686, D3S32 and D3S30 polymerase chain reaction-
restriction fragment length polymorphism (PCR-RFLP)
analysis of normal and tumour samples was performed
using one or two rounds of PCR analysis (Sundaresan et al.,
1992). Amplification was performed in a volume of 50 ,ul
containing 5 ,l of DNA solution or 50 ng of genomic DNA.
An aliquot of 15 4ul of the product was digested with 10 units
of the appropriate restriction enzyme. The digests were
fractionated on 4% agarose gels, stained with ethidium
bromide and photographed.
PCR primers for 13 polymorphic microsatellite markers
(see Table I) were obtained from Research Genetics,
Huntsville, USA, or synthesised locally. One of the primers
was end-labelled with [y-32P]ATP and PCR products
generated from standard reactions. Products were separated
by gel electrophoresis in denaturing 8% polyacrylamide-8 M
urea and autoradiographed overnight. Labelled M13mp8 was
included as a sequencing ladder to facilitate sizing of the
alleles. The likely map positions of the markers (see Table I)
are given as indicated by the Sigma mapping program using
data from the Genome Data Base, The Johns Hopkins
University (Naylor et al., 1994).
Matched tumour and normal samples were evaluated
subjectively and by computer-assisted quantitative densito-
metry using Gel Base Pro image software. Allele loss was
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September 1995Table I Polymorphic markers used and LOH at each locus
Map position
3p26.5
3p26.2-25.3
3p26.1 -24.2
3p26.1 -25.1
3p24.3
3p24.2
3p24.1 -22.1
3p22.1 -21.2
3p2l.3
3p2l.32-21.31
3p22.1 - 14.2
3pl4.2- 14.1
3pl3
3pl3
3pl2.3- 12.1
3p27 -8
3p22 -24
Allelic lossl
informative cases (%)
2/36 (5)
5/37 (13)
8/34 (23)
6/33 (18)
5/33 (15)
10/44 (23)
4/30 (13)
10/28 (36)
11/38 (29)
9/38 (24)
2/29 (7)
4/31 (13)
4/25 (16)
6/36 (17)
12/32 (37)
3/31 (10)
1/24 (4)
scored if the signal of one of the alleles was reduced by
approximately 50% when DNA from the tumour was
compared with normal. Constitutional homozygosity was
taken to be non-informative. PCR-based techniques may not
distinguish between allele loss and gain, thus alteration in the
intensity of alleles is often designated allele imbalance rather
than LOH. However, when analysing this series of matched
samples we only rarely detected overamplification of one
allele with loss or reduced intensity of the matching allele
when comparing normal and tumour samples. Furthermore
as the alleles showing reduced intensity were within regions
considered to harbour tumour-suppressor genes, these results
suggest that the allele imbalance detected is likely to be due
to LOH. The Mann-Whitney, chi-square and Fisher's exact
tests and Spearman correlation coefficients were used for
statistical analysis of the results. Survival curves were
obtained by the Kaplan-Meier survival method and
analysed by the log-rank test.
Results
A total of 48 primary oral SCCs were screened for LOH at
3p. A summary of the clinical and histological features is
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given (Table II). The percentage of informative cases with
loss at each locus varied between 0% and 37%, (Table I).
When all loci were considered the overall LOH for 3p was
34/48 (71%). In this study the frequency of LOH for loci at
3q was 4-10%. This is lower than the incidence of 10-15%
random loss reported for other studies ofhead and neck SCC
(Ah-See et al., 1994; Narwoz et al., 1994; Naylor et al., 1994)
and may reflect the high percentage of early stage 1 and 2
tumours examined. The frequency of LOH at D3S1307,
D3S647 and D3S1076 was below the threshold for random
loss at 3q and these loci were considered to lie outside of the
regions which may contain suppressor genes.
Examination of the pattern of LOH reveals interstitial
losses at three regions at this chromosome arm. Allelic
deletion at a single region occurred in 19/48 (40%) cases, 15/
48 (31%) showed deletion of two or three regions and 14
cases retained heterozygosity at all informative loci. The
likely map positions of the markers (Figure la) and the
extent of single and multiple deletions is summarised
diagrammatically (Figure lb). The map position of some of
the markers used has not been precisely defined and in this
schematic representation the order of the markers is shown
after taking into account the likely map positions together
with the pattern of allelic deletions in the tumours examined.
When alleles were lost in the tumour, loss was not always
complete owing to contamination of the sample with normal
cells. A series of representative cases is shown (Figure 2).
The highest frequency of LOH was seen at 3p24-pter with
18/48 (37%) of combined cases informative at loci between
D3S1038 and THRB showing LOH. Cases 5 and 32 show a
single interstitial deletion involving THRB suggesting that
this locus may be close to a tumour-suppressor gene. The
overall pattern of deletions within this region suggests that
LOH at 3p24 and 3p25-pter may occur independently.
However, as only five cases show allelic deletion at D3S1038
while retaining heterozygosity at D3S1293 or THRB, no firm
conclusions can be made until further cases have been
analysed and the exact map order of the markers is
established.
The second region of deletion was at 3p2l.3 -22.1 with 17/
48 (35%) ofcombined cases showing allele loss at loci between
D3S32 and D3S966. Two cases (22 and 27) showed an
interstitial deletion at D3S32. However many of the tumours
examined showed deletion at two or more of loci at D3S32,
D3S686 and D3S966. Based on the likely map positions of
these markers (Figure 1a) this suggests that a tumour-
Table II Clinical and histological features of oral SCC
Feature Category LOHpositive LOH negative
Age Average and range 59.3 (36-84) 63.9 (34-88)
Site Floor of mouth 11 3
Alveolus 10 1
Tongue 6 5
Retromolar fossa 2 1
Bucca mucosa 5 3
Palate 0 1
Sex Male 22 7
Female 12 7
Tumour stage 1 3 5
2 11 6
3 9 2
4 11 1
Smoking Non smokers 16 4
Moderate (<20 day-1) 11 6
Heavy (>20 day-) 6 3
Alcohol Never 13 8
Incidental 6 4
Moderate (1-4 units day-') 6 1
Heavy (>4 units day-l) 9 1
Lymph node status Positive 15 2
at histology Negative 18 12
Degree of tumour Well 23 10
differentiation Moderate 9 1
Poor 2 3
Locus/symbo
D3S1307
D3S1038
D3S192
D3S1007
D3S1293
THRB
D3S647
D3S32
D3S686
D3S966
D3S1076
D3S1228
D3S1079
D3S659
D3S30
D3S196
D3S1764Prognostic significance of LOH at 3p in oral SCC
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S11111 Ii 3
D3S1307 D3S1293 D3S32 D3S1079
D3S1038 THRB
D3S1007
D3S192
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D3S647 D3S966
D3S1076
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* Loss of heterozygosity a Non-informative Retain heterozygosity
Figure 1 (a) Map positions of the markers used at 3p as indicated by the Sigma mapping program using data from the Genome
Data Base. (b) Deletion map of chromosomal regions with partial loss at 3p. The markers used are shown on the left. The order of
the markers is given after taking into account the likely map positions together with mapping information provided by the pattern
of allelic deletions in the tumours examined. The case numbers are at the top. Cases 1-20 show LOH at one of the commonly
deleted regions identified at 3p, cases 21-34 show deletions at two or three of these regions, cases 35-48 retain heterozygosity at all
loci tested.
suppressor gene is located close to 3p2l.33. Fifteen of 47
(31%) informative combined cases showed interstitial dele-
tions at loci between D3S30 and D3S1228 (3pl2.1- 14.2)
adding a third target for a tumour-suppressor gene close to
D3S30.
We compared our results with clinicopathological features
for each tumour. Single deletions at 3pl2.1- 14.2 and
3p2l.3-22.1 were more frequent in early stage 1 and 2
tumours whereas multiple losses at 3pl2.1-14.2 and 3p2l.3-
22.1 and 3p24-pter were seen in advanced tumours.
When analysing the results we considered the number of
regions showing LOH at 3p rather than the number of
deleted loci (as several tumours show loss of adjacent loci
within a commonly deleted region). Study of potentially
malignant lesions also reveals that deletion at several adjacent
loci occur in premalignant lesions (Emilion et al., 1995).
There was a significant correlation between the number of
deleted regions at 3p and presence of positive lymph nodes at
histological examination (U= 137, P=0.004) and tumour
stage (r,=0.586, P<0.001, Figure 3).
We also compared the presence or absence ofLOH at any of
the loci examined at 3p (as LOH +/LOH-) to analyse the
results in relation to other clinicopathological parameters and
known risk factors for oral cancer. LOH +/LOH - at 3p was
compared among the three histological groups well-, moder-
ately and poorly differentiated but no correlation was found
(chi-square 4.10, P0.12) and there was no relation between
smoking habits and LOH at 3p (Chi-square 3.87, P0.14) or
alcohol consumption (chi-square 1.2, P0.55, moderate and
heavy drinkers were combined for statistical analysis).
We calculated the overall survival time from the date of
tumour diagnosis. Analysis of this survival data showed that
LOH at 3p is associated with a significant reduction in mean
survival time and is a marker of poor prognosis (log-rank
5.13, P0.023, Figure 4a). Only three advanced stage 3 or 4
tumours show no LOH at 3p. Separation of the cases into
early (stage 1 and 2) and advanced stage tumours identifies a
subgroup of patients with aggressive early disease associated
with reduced overall survival, (log-rank 5.32, P0.021, Figure
4b). LOH at 3p also reduces the disease-free survival time
[
D3S1228 D3S30
b
D3S659
D3S1307
D3S1038
D3S192
D3S1007
D3S1293
THRB
D3S647
D3S32
D3S686
D3S966
D3Sl076
D3S1228
D3S1079
D3S659
D3S30
D3S196
D3S1764
Common
area of
deletion
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D3S32
T N
D3S30
T N
4- 4-
D3S1228 D3S659
T N T N
-4-
.4--
D3S1228 D3S30
T N T N
--Al
*-A2
Figure 2 Examples of LOH at D3S192 (case 2), D3S32 (case 8), THRB and D3S30 (case 26). All cases retain heterozygosity at the
other loci shown. Markers were amplified from DNA derived from blood (N) and tumour (T). The numbering of the patients is the
same as used in Table I. +-, alleles detected by microsatellite assay. Al and A2 represent the polymorphic alleles detected by RFLP
analysis. The signal from the smaller second allele is not readily detected in some cases.
(log-rank 4.08, P0.043, Figure 4c). Although these results
demonstrate that LOH at 3p correlates with reduced survival,
the number of cases examined is insufficient to permit
multivariate analysis to see whether this association would
remain significant when other known prognostic markers are
taken into account.
Discussion
Our previous studies of LOH at 3p for primary oral SCCs
showed allele loss in 81% of informative cases (Partridge et
al., 1994). A subsequent study has shown loss in 52% of
D3S192
T N
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T N
D3S647
T N
4-
4-0 - Al
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4-Al
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-Al
4- A2
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--Al
4-A2
--A2
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--Al
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1 2 3
Tumour stage
Figure 3 Relationship between tumour stage and
commonly deleted regions at 3p. Commonly delete
M, 2; EZ1, 1; E=, 0.
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A ~ ~~~~ 0
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Figure 4 Influence of LOH at 3p on (a) overall si
all cases, (b) overall survival time for stage 1 and
disease-free survival time for all cases.
these tumours and suggests three regions of 1
1994). In this study the frequency of LOH a
and the data confirms at least three regions of
for oral cancer. Similar results have been sugi
and neck SCC and other tumour types (Yokc
Jones and Nakamura, 1992; Hibi et al., 1993; Kohono et al.,
1993; Maestro et al., 1993; Chen et al., 1994; Wu et al., 1994)
and together support the existence of several tumour
suppressor genes at chromosome 3p.
Allele loss at 3pl2.1-14.2 and 3p2l.3-22.1 was seen in
early stage 1 and 2 disease suggesting that LOH at these
chromosomal regions is an early event in tumour develop-
ment. The recent finding of LOH at 3p in 53% ofpotentially
malignant oral lesions supports this view (Emilion et al.,
1995). Allele loss towards the telomere at 3p24-pter was
more common in advanced stage 3 and 4 oral SCC and may
be associated with tumour progression. This view is
4 supported by the finding of 56% LOH at 3p26 for a series
of head and neck cancers (Li et al., 1994), 94% of the cases
in this series were advanced stage 3 or 4 tumours.
the number of Previous deletion mapping studies on 3p have highlighted
d regions: *, 3 deletions at 3p24-pter, 3p2l.1-23 and 3pl2-14 (Yokota et
al., 1989 Hibi et al., 1993; Kohono et al., 1993; Maestro et
al., 1993; Chen et al., 1994; Partridge et al., 1994). The most
commonly deleted region in this study was between 3p24-
pter, a finding recently reported for head and neck cancer
(Li et al., 1994). The second most frequently deleted region
was at 3p2l.3-22.1. Earlier studies have also indicated that
an area at 3p2l-23 is frequently deleted in head and neck
and oral cancer (Maestro et al., 1993; Wu et al., 1994). The
majority of cases analysed in this series show loss of two or
more loci at D3S32, D3S686 and D3S966. The likely
LOH -(n= 14) chromosomal locations of these markers and the pattern
i Mean survival of deletions suggests that a tumour-suppressor gene lies time 74 months
close to D3S21.3. The third commonly deleted region was
survival towards the centromere at 3pl2.1-14 with the pattern of
38 months deletions suggesting that a suppressor gene also lies close to
T- D3S30.
10 Several tumour-suppressor genes located at 3p have
already been identified and may play a role in the
pathogenesis of lung, renal, breast, female genital tract,
head and neck and oral cancer. The gene responsible for von
Hippel-Lindau syndrome with inherited susceptibility to
various neoplasms, is at 3p25 (Shuin et al., 1994) and the
oLOH - (n= 11) retinoic acid receptor P gene, which is deleted in several
Mean survival cancer types is at 3p23-4 (Mattei et al., 1988). PTP-y (La
time 102 Forgia et al., 1991) is a candidate suppressor gene recently months reassigned to 3pl4 and the renal cancer gene NRCI also lies
within 3pl4-12 (Sanchez et al., 1994). Whether the same
genes are implicated in all of these tumours or specific
suppressor genes exist for some tumour types has yet to be
1o determined. The two cases with interstitial deletions at THRB
(case 5 and 32) and the single deletion at D3S32 (case 27) will
facilitate mapping of the suppressor genes at the regions
iclentifiecA
Since the findings are broadly similar to those reported for
lung cancer (Hibi et al., 1993) it has been suggested that the
common regions of deletion at 3p may be a reflection of the
contribution of tobacco to the pathogenesis of these lesions.
However this study failed to demonstrate an association with
= 14) tobacco consumption, (or high alcohol intake, another risk
factor for oral cancer) and allele loss at 3p.
The significant correlation between the number of deleted
regions at 3p and tumour stage is consistent with the concept
that the progressive accumulation of genetic events is
associated with advanced disease (Fearon and Vogelstein,
1990). This study has also demonstrated that LOH at 3p is an
important marker of reduced survival for early stage oral
SCC and identifies a subgroup of patients with aggressive
urvival time for disease who should receive more aggressive treatment. Based
12 tumours. (c) on our present knowledge and experience we would advocate
wider resection margins and prophylactic treatment of the
neck by surgery or radiotherapy to give these patients the
best possible chance of long-term survival. Frequent,
meticulous follow-up of these cases is also indicated. At
loss (Wu et al., present there is no proven adjuvant therapy that can reduce
it 3p was 71% the risk of distant metastasis in patients treated for oral
f deletion at 3p cancer. Prospective studies using the new, better-tolerated
gested for head retinoid derivatives should be initiated for this subgroup of
)ta et al., 1989; patients.
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